title: Brief communication: electromagnetic fields improve visuospatial performance and reverse agraphia in a parkinsonian patient.
abstract: A 73 year old right-handed man, diagnosed with Parkinson's disease (PD) in 1982, presented with chief complaints of disabling resting and postural tremors in the right hand, generalized bradykinesia and rigidity, difficulties with the initiation of gait, freezing of gait, and mild dementia despite being fully medicated. On neuropsychological testing the Bicycle Drawing Test showed cognitive impairment compatible with bitemporal and frontal lobe dysfunction and on attempts to sign his name he exhibited agraphia. After receiving two successive treatments, each of 20 minutes duration, with AC pulsed electromagnetic fields (EMFs) of 7.5 picotesla intensity and 5 Hz frequency sinusoidal wave, his drawing to command showed improvement in visuospatial performance and his signature became legible. One week later, after receiving two additional successive treatments with these EMFs each of 20 minutes duration with a 7 Hz frequency sinusoidal wave, he drew a much larger, detailed and visuospatially organized bicycle and his signature had normalized. Simultaneously, there was marked improvement in Parkinsonian motor symptoms with almost complete resolution of the tremors, start hesitation and freezing of gait. This case demonstrates the dramatic beneficial effects of AC pulsed picotesla EMFs on neurocognitive processes subserved by the temporal and frontal lobes in Parkinsonism and suggest that the dementia of Parkinsonism may be partly reversible.
authors.affiliation: Department of Neuroscience, Touro College, Dix Hills, NY 11746, USA.
authors.forename: R
authors.initials: R
authors.lastname: Sandyk
mesh_terms: D000368:Aged; D000381:Agraphia / Q000209:etiology / Q000628:therapy*; D000978:Antiparkinson Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D004574:Electromagnetic Fields; D005684:Gait / Q000528:radiation effects; D006801:Humans; D008280:Magnetics / Q000627:therapeutic use*; D008297:Male; D009483:Neuropsychological Tests; D010300:Parkinson Disease / Q000150:complications / Q000188:drug therapy / Q000523:psychology / Q000628:therapy*; D011597:Psychomotor Performance / Q000528:radiation effects*; D013037:Spatial Behavior / Q000528:radiation effects*; D014202:Tremor / Q000209:etiology / Q000532:radiotherapy; D014796:Visual Perception / Q000528:radiation effects*
chemical_list: D000978:Antiparkinson Agents